{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-026177","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.819829+00:00","generated_at":"2026-06-22T05:17:20.352282+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atossa Q3 2022: cash $117.5M, no revenue; FDA authorizes Phase 2 endoxifen study","bullets":["Cash, cash equivalents and restricted cash $117.5M as of Sep 30, 2022; no revenue in Q3.","Operating expenses $8.2M in Q3 2022, up 59% YoY; R&D $5.2M (+134%) on higher trial costs.","FDA authorized Phase 2 neoadjuvant (Z)-endoxifen for ER+/HER2- breast cancer; enrollment expected Q4 2022.","Invested in privately-held Dynamic Cell Therapies (CAR-T); paid $300K for exclusive negotiation right.","Completed dosing in Parts B and C of Phase 1/2a AT-H201 trial for lung injury from cancer treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-026177","json":"https://secwatch.observer/filing/0001437749-22-026177.json","markdown":"https://secwatch.observer/filing/0001437749-22-026177.md","text":"https://secwatch.observer/filing/0001437749-22-026177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000143774922026177/0001437749-22-026177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000143774922026177/atos20221103_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:17:20.352282+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f02fd81b1b8012174afe0e94db3cef4d52863c6","claim":"ATOSSA THERAPEUTICS, INC. reported the fiscal quarter ended September 30, 2022 results: revenue no source of revenue.","evidence_excerpt":"Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774922026177/0001437749-22-026177-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended September 30, 2022"},{"label":"Revenue","value":"no source of revenue"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}